Yvonne T.M. Tsang

Dr. Yvonne T.M. Tsang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
EKErin R. King
Erin R. King
ZZZhifei Zu
Zhifei Zu
YTYvonne T.M. Tsang
Yvonne T.M. Tsang
MDMichael T. Deavers
Michael T. Deavers
AMAnais Malpica
Anais Malpica
KWKwong-Kwok Wong
Kwong-Kwok Wong

Verified
Journal Article
Open access
PDF file
HSHuijuan Song
Huijuan Song
SKSuet-Yan Kwan
Suet-Yan Kwan
DIDaisy I. Izaguirre
Daisy I. Izaguirre
ZZZhifei Zu
Zhifei Zu
YTYvonne T.M. Tsang
Yvonne T.M. Tsang
KWKwong-Kwok Wong
Kwong-Kwok Wong
PAX2 is one of nine PAX genes that regulate tissue development and cellular differentiation in embryos. However, the functional role of PAX2 in ovarian cancer is not known. Twenty-six ovarian cancer cell lines with different histology origins were screened for PAX2 expression. Two ovarian cancer cell lines: RMUGL (mucinous) and TOV21G (clear cell), with high PAX2 expression were chosen for further study. Knockdown PAX2 expression in these cell lines was achieved by lentiviral shRNAs targeting the PAX2 gene. PAX2 stable knockdown cells were characterized for cell proliferation, migration, apoptosis, protein profiles, and gene expression profiles. The result indicated that these stable PAX2 knockdown cells had reduced cell proliferation and migration. Microarray analysis indicated that several genes involved in growth inhibition and motility, such as G0S2, GREM1, and WFDC1, were up-regulated in PAX2 knockdown cells. On the other hand, over-expressing PAX2 in PAX2-negative ovarian cell lines suppressed their cell proliferation. In summary, PAX2 could have both oncogenic and tumor suppression functions, which might depend on the genetic content of the ovarian cancer cells. Further investigation of PAX2 in tumor suppression and mortality is warranty.

19 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
DIDaisy I. Izaguirre
Daisy I. Izaguirre
CNChun Wai Ng
Chun Wai Ng
SKsuet yan kwan
suet yan kwan
EKEucharist Kun
Eucharist Kun
YTYvonne T.M. Tsang
Yvonne T.M. Tsang
KWKwong-Kwok Wong
Kwong-Kwok Wong
Background: The standard treatment of ovarian cancer is surgery followed by a chemotherapeutic combination consisting of a platinum agent, such as cisplatin and a taxane-like paclitaxel. We previously observed that patients with ovarian cancer wild-type for p53 had a poorer survival rate than did those with p53 mutations. Thus, a better understanding of the molecular changes of epithelial ovarian cancer cells with wild-type p53 in response to treatment with cisplatin could reveal novel mechanisms of chemoresistance. Methods: Gene expression profiling was performed on an ovarian cancer cell line A2780 with wild-type p53 treated with cisplatin. A gene encoding a secretory protein growth differentiation factor 15 (GDF15) was identified to be highly induced by cisplatin treatment in vitro. This was further validated in a panel of wild-type and mutant p53 ovarian cancer cell lines, as well as in mouse orthotopic models. The mouse tumor tissues were further analyzed by histology and RNA-seq. Results: GDF15 was identified as one of the highly induced genes by cisplatin or carboplatin in ovarian cancer cell lines with wild-type p53. The wild-type p53-induced expression of GDF15 and GDF15-confered chemotherapy resistance was further demonstrated in vitro and in vivo. This study also discovered that GDF15-knockdown (GDF15-KD) tumors had less stromal component and had different repertoires of activated and inhibited canonical pathways in the stromal cell and cancer cell components from that of the control tumors after cisplatin treatment. Conclusions: GDF15 expression from the wild-type p53 cancer cells can modulate the canonical pathways in the tumor microenvironment in response to cisplatin, which is a possible mechanism of chemoresistance.